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ABSTRACT
Introduction: Persons living with human
immunodeficiency virus (HIV) are living longer
and at risk of non-communicable diseases,
including diabetes mellitus (DM). Both HIV and
DM place patients at risk of peripheral neuropathy (PN). Our aim was to demonstrate the
prevalence and characteristics of PN in our
population of patients with HIV infection
compared with concomitant HIV and DM.
Methods: A prospective cross-sectional study
was performed at the Aga Khan Hospital in
Nairobi, Kenya. Data were collected on
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demographics and characteristics of DM and
HIV. Symptoms and signs of PN were evaluated
by Neuropathy Symptom Score, Neuropathy
Disability Score, and 10 g monofilament testing.
Results: Two groups were recruited, each consisting of 68 patients: (1) HIV only, (2) HIV and
DM. The median age of patients was 51 years
(IQR 42.8–58.6) and 55% were male. Median
duration for HIV was 10 years (IQR 5–12) with a
median CD4 count of 524 cells/mm3 (IQR
369–731). Median duration for DM was 1 year
with a median glycosylated hemoglobin of
6.7% (IQR 6.6–7.6). Sixty-nine percent of
patients with HIV had suppressed viral loads,
and 9 patients (6.6%) had a history neurotoxic
antiretroviral therapy use. PN was detected in
11 (16%) HIV-only patients, and in 17 (25%)
participants who had both HIV and DM (Fisher
exact test chi-square = 0.4). Univariate analysis
demonstrated older age, high body mass index,
and long duration of HIV were associated with
an OR of 1.07 (95% CI 1.02–1.11), 1.21 (95% CI
0.46–3.11), and 1.07 (95% CI 0.99–1.15) in the
overall group, respectively.
Conclusion: Our study demonstrates a higher
but non-significant prevalence of PN in patients
with both HIV and DM when compared to HIV
alone. HIV disease control had no association
with PN presence.
Keywords: Peripheral
Diabetes; Kenya

neuropathy;

HIV;
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Key Summary Points
The prevalence of human
immunodeficiency virus (HIV) is high in
sub-Saharan Africa, a region which also
has a huge burden of undiagnosed
diabetes mellitus (DM).
The study aimed to establish the
prevalence of and risk factors for
peripheral neuropathy (PN), a
complication of both HIV and DM, in
patients with both these chronic
conditions.
Results from the study showed a higher
burden of PN in patients with both HIV
and DM compared with HIV alone.
The study identified old age, high BMI,
and long duration of HIV as risk factors for
development of PN in the study
population.
This forms the basis for future projects on
quality of life in patients with PN and
living with concurrent HIV and DM.

INTRODUCTION
The population infected with human immunodeficiency virus (HIV) is ageing and will
increasingly develop non-communicable diseases [1]. Antiretroviral therapy (ART) has lessened the burden of morbidity and mortality
amongst people living with HIV [2, 3]. Prophylaxis against opportunistic infections and the
prevention of mother to child transmission of
HIV have resulted in increased life span of
patients with HIV and higher child survival
gains, respectively [4]. In Kenya, these factors
have resulted in a reduction of acquired
immunodeficiency syndrome (AIDS)-related
deaths by 48% since 2010. The current prevalence of HIV in the country is 4.9% [5].
Noninfectious comorbidities including diabetes mellitus (DM) have a higher prevalence in

HIV-positive patients than in age-matched
controls [6, 7]. The prevalence of DM has been
rapidly increasing in middle- and lower-income
countries and it is predicted that the number of
adults living with DM in Africa will more than
double between 2017 and 2045. The region is
also estimated to have the highest number of
undiagnosed cases of DM. In Kenya, the prevalence is estimated at 2% [8].
HIV and DM demonstrate a bidirectional
effect on each other. Poor glycemic control
occurs in HIV-positive patients with type 2 DM
[9]. A positive association has been demonstrated between antiretroviral drugs that cause
lipodystrophy and the development of DM [10].
Neuropathy can occur independently in both
HIV infection and DM. The main pattern of HIV
infection is distal symmetric polyneuropathy
(DSP) primarily of a small (c) fiber origin, which
has similar features to diabetic neuropathy [11].
The prevalence of HIV neuropathy from a systematic review showed great variation with
estimates ranging from 1.2% to 69.4% [12]. The
proposed etiologies of DSP in HIV are peripheral
nerve injury associated with the presence of HIV
in the immune cells component of the peripheral nerves [13] and neurotoxic effects of
antiretroviral drugs. Studies about the association among CD4 count, viral load, and risk of
peripheral neuropathy (PN) have been conflicting [14, 15]. Diabetic neuropathy is the most
common cause of PN worldwide [16]. DSP is a
clinical diagnosis that is suggested by the presence of typical symptomatology and symmetrical distal sensory loss or typical signs in the
absence of symptoms in a patient with DM [17].
The continued survival of people living with
HIV predisposes them to age-related comorbidities as well as side effects from the use of
ART. Many HIV neuropathy studies exclude
patients with DM. Therefore, the interaction
has been poorly described. This study aims to
investigate the combination of risk factors
demonstrated to be associated with PN in HIV
with or without DM. The prevalence of neuropathy in patients will provide a basis for
future investigations into the health status and
quality of life amongst the growing number of
age-related comorbidities in persons living with
HIV/AIDS.
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METHODS
The study was conducted at the Aga Khan
University Hospital, Nairobi (AKUHN), a private
nonprofit teaching hospital. The facility has
international accreditation by the Joint Commission International, and the laboratory has
been accredited by the South African National
Accreditation System (SANAS) and the College
of American Pathologists. An average of 700
patients are followed up per year at the infectious disease clinic of the institution. CD4
counts and HIV viral load testing are performed
at baseline and every 6 months. Metabolic
panels including glycated hemoglobin (HbA1c),
lipid profile, and renal and liver function tests
are performed annually.
Study Participants
Eligible participants were at least 18 years old
and assigned to one of two groups: (1) HIV
positive; (2) both HIV positive and with DM.
Exclusion criteria included a history of neuropathy due to non-HIV or non-diabetic cause,
namely alcoholism, amyloidosis, autoimmune
disorders, chronic kidney failure, connective
tissue disease, infectious disease, liver failure,
and vitamin B12 deficiency.
Protocol Approval and Patient Consent
Ethical approval was sought from the Institutional Ethics and Review Committee at the
AKUHN (Ref. No. 2018/REC-121) prior to conducting the study. The study was conducted in
accordance with the Declaration of Helsinki
1964 and its later amendments. Informed consent was signed by the participants prior to
enrollment into the study.
Study Procedures
This was a prospective, cross-sectional study
that enrolled patients from August 2020 to
March 2021. Demographic, clinical, and laboratory data were obtained from the patient’s
records. Each consenting participant was tested

for the presence of PN using both a questionnaire for symptoms and clinical testing. The
Neuropathy Symptom Score (NSS) (see Supplementary Material) was administered which is a
validated tool to diagnose the presence and
severity of neuropathy. It consists of questions
probing for gait instability, burning sensation,
numbness, pricking sensation and autonomic
symptoms [18]. A clinical examination was
undertaken by application of components of
the Neuropathy Disability Score (NDS) (see
Supplementary Material) and monofilament
testing using a 10-g nylon filament. Neuropathy
testing was performed by an internal medicine
resident after training by a neurologist (D.S.)
and an endocrinologist (U.A.). The NDS is a
validated tool that evaluates both small and
large fiber neuropathy in the lower limbs by
testing the perception of pain, vibration, temperature, and ankle reflexes [1].
Peripheral neuropathy was defined as at least
one neuropathy symptom on the NSS and at
least one sign on either the NDS or a positive
monofilament testing.
Statistical Analysis
Categorical data such as gender, ethnicity, and
alcohol use are presented as frequencies and
percentages, whereas continuous data such as
age, body mass index (BMI), CD4 count, HIV
viral load, and current HbA1c are presented as
medians and interquartile ranges (IQR). Continuous data was further tested for normality
using Shapiro–Wilk test. Univariate analyses
were conducted using Fisher’s exact test for
categorical variables and Kruskal–Wallis test for
continuous variables when comparing the
associations between the two groups (HIV vs
HIV with DM). A logistic regression model was
used to estimate the association between the
risk factors and peripheral neuropathy status.
The electronic database of the commercially
available Statistical Package for Social Sciences
(SPSS) version 25 was used to perform the
analysis. Variables with a p value of less than
0.10 were included in the multivariate model
whereas a p value of less than 0.05 was considered significant.
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RESULTS
A total of 150 patients were assessed for eligibility for inclusion into the study. Five patients
declined consent, four were ineligible owing to
meeting exclusion criteria, and five were
excluded from the study because of inadequate
data. Therefore 136 patients, with 68 in each
study group, were included in the final analysis.
Figure 1 depicts the flow of the study.
Demographic Characteristics of Study
Population
The median age of the participants in the HIV
and DM group was higher at 55.6 years (IQR
47.2–60.4) than the 51.0 years (IQR 42.3–58.6)
in the HIV only category (p \ 0.001). Fifty-five
percent (n = 75/136) of the total participants
were male, accounting for 51.5% and 46.9% in
the HIV-only and concurrent HIV and DM
groups, respectively. Overall, 98.5% of the participants were Africans. The other differences in

Fig. 1 Study ﬂowchart

demographic characteristics are detailed in
Table 1.
Disease Characteristics
In the HIV-only and concurrent HIV and DM
groups, the median duration since diagnosis of
HIV was 8.5 (IQR 4.0–12.0) and 10.5 (IQR
6.0–13.5) years, respectively (Table 2). The current median CD4 count was 490 (IQR 356–680)
and 588 (IQR 387–799) in the HIV-only and
concurrent HIV and DM groups, respectively
(p = 0.087). The proportion of patients with
either undetectable or less than 20 copies (the
laboratory cutoff range) of HIV RNA detected
was 69.1%. Ninety-four percent of the total
study population were on ART and only nine
had a history of use of neurotoxic ART medications. In the concurrent HIV and DM group,
the mean duration of period of follow-up for
DM was 3.85 years. The average HBA1c was
7.65%.
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Table 1 Demographic characteristics of study population
Variables

Age (years)

Total

HIV only

HIV 1 DM

N = 136

N = 68

N = 68

P value

\ 0.001

51.0

[42.3, 58.6]

46.9

[38.7, 53.7]

55.6

[47.2, 60.4]

Male

75

55.1%

35

51.5%

40

58.8%

Female

61

44.9%

33

48.5%

28

41.2%

African

134

98.5%

66

97.1%

68

100.0%

Asian

2

1.5%

2

2.9%

0

0.0%

Height (cm)

169.0

[162.0, 174.5]

168.0

[160.0, 175.0]

169.5

[162.0, 173.0]

0.772

Weight (Kg)

75.0

[70.0, 85.5]

75.0

[70.0, 85.0]

77.5

[70.0, 88.5]

0.147

Gender
0.491

Ethnicity
0.496

DM diabetes mellitus, HIV human immunodeﬁciency virus

Prevalence of Neuropathy
Neuropathic symptoms were reported by about
a third of the participants, with no significant
differences in the two groups (HIV only, 33.8%;
HIV and DM, 30.9%) (Table 3). The HIV and
DM group had a higher proportion of detected
abnormalities with 27 (39.7%) patients while
the HIV-only group had 16 patients (23.5%).
The most common detected abnormality on
neurological examination was absent reflexes.
(A detailed table of NDS findings is available in
the Supplementary Material.)
The diagnosis of PN required the presence of
at least one symptom and at least one sign. This
criterion was met by 20.6% of the participants
(HIV only, 16%; HIV and DM, 25%; see Fig. 2).
Risk Factors Associated with Neuropathy
In the overall cohort, older age, BMI and duration of HIV were not significantly associated
with PN. Older age had odds ratio (OR) of 1.04;
95% confidence interval (CI) 0.979–1.102, and
OR 1.09; 95% CI 1.019–1.175 in the HIV only
and concurrent HIV and DM cohorts, respectively. In the HIV-only group, the period of HIV
treatment had an OR 1.08 (95% CI 0.960–1.219)
while the OR was 1.06 (95% CI 0.962–1.156) in

the concurrent HIV and DM group. Both the
CD4 count at diagnosis of HIV and the current
CD4 count had no effect on the presence of
neuropathy in both groups. Suppression of viral
load was not associated with peripheral neuropathy in the two groups. The findings are
shown in Table 4.

DISCUSSION
In view of the increasing coexistence of noncommunicable disease in patients with HIV, our
study aimed to show the burden of one of the
complications of both HIV and DM. We identified an overall prevalence of 20.6% in the 136
participants. Comparatively, the prevalence in
the HIV and DM group was higher than in the
HIV-only
group
(25.0%
and
16.2%,
respectively).
The prevalence of PN in HIV has varied
markedly in previous studies depending on the
population studied and the diagnostic criteria
utilized. Studies that have included both signs
and symptoms have shown a range of prevalence of PN in HIV from 4% to 40% [15, 19–24].
Most of these reports utilized the Brief PN
Screen (BPNS), a validated tool that assesses
both the symptoms and signs of neuropathy
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Table 2 Disease characteristics of HIV and diabetes mellitus
Variables

Total

HIV only

HIV 1 diabetes

N = 136

N = 68

N = 68

P value

HIV duration (years)

10.0

[5.0, 12.0]

8.5

[4.0, 12.0]

10.5

[6.0, 13.5]

0.071

CD4 count at diagnosis

200.0

[65.5, 400.0]

162.5

[50.0, 378.0]

242.5

[76.0, 429.5]

0.220

Recent CD4 count

524.5

[369.0, 731.0]

490.0

[356.0, 680.0]

588

[387.5, 799.0]

0.087

Undetectable/\ 20

94

69.1%

48

70.6%

46

67.6%

0.853

Detectable

42

30.9%

20

29.4%

22

32.4%

Yes

129

94.9%

65

95.6%

64

94.1%

None

7

5.1%

3

4.4%

4

5.9%

Recent HIV-1 RNA count

Current ART use
0.648

History of previous neurotoxic ART use
Yes

9

6.6%

3

4.4%

6

8.8%

0.493

No

127

93.4%

65

95.6%

62

91.2%

Duration of diabetes (years)

–

–

1.0

[0.5, 6.0]

–

HbA1c (%)

–

–

6.7

[6.6, 7.6]

–

Total cholesterol (mmol/L)

–

–

4.5

[3.7, 5.2]

–

HDL cholesterol (mmol/L)

–

–

1.1

[0.6, 1.5]

–

LDL cholesterol (mmol/L)

–

–

2.7

[2.2, 3.4]

–

Triglycerides (mmol/L)

–

–

1.7

[1.2, 2.3]

–

Data are presented as the number (%) of patients or median (25th and 75th percentile) values
ART antiretroviral therapy, HbA1c glycated hemoglobin, HDL high density lipoprotein, LDL low density lipoprotein,
RNA ribonucleic acid
[20]. The prevalence of 20.6% in the overall
cohort of our study is comparable to the range
exhibited in the aforementioned reports. Conversely, a high estimate of 59% was reported in
Rwanda by Tumusiime et al. [25] 21% of the
participants were on an ART regime containing
a neurotoxic drug, stavudine, compared to our
population among whom only 6.6% reported
previous use.
Our study reported a higher prevalence in
the HIV and DM group compared to the HIVonly group. Previous studies in the African
region have either excluded patients with DM
or did not have any patients with a history of
DM among their participants. A study done in

South Africa listed DM as an exclusion criterion
due to the confounding in the diagnosis of HIVassociated PN [24]. Studies of PN in patients
with HIV in Kenya [15] and Uganda [26] did not
include participants with a known history of
DM. Nonetheless, a history of DM was shown to
confer an additional risk of PN in HIV in other
reports, including Evans et al., who demonstrated an OR of 1.57 (95% CI 0.96–2.59,
p = 0.080) with history of DM in asymptomatic
PN and a significant association of OR 3.15
(95% CI 1.74–5.70, p = 0.001) in symptomatic
PN amongst patients with HIV [19]. A different
report by Anziska and colleagues reported a
history of DM in 19.2% of the participants
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Table 3 Neuropathy Symptom Score results
Variables

Total

HIV only

HIV 1 diabetes

N = 136

N = 68

N = 68

P value

Neuropathy symptoms
Symptoms of unsteadiness when walking
Yes

6

4.4%

1

1.5%

5

7.4%

No

130

95.6%

67

98.5%

63

92.6%

0.208

Burning, aching pain, or tenderness in legs or feet
Yes

23

16.9%

16

23.5%

7

10.3%

No

113

83.1%

52

76.5%

61

89.7%

0.066

Pricking sensations on legs and feet
Yes

20

14.7%

7

10.3%

13

19.1%

No

116

85.3%

61

89.7%

55

80.9%

0.226

Regions of numbness on legs and feet
Yes

22

16.2%

9

13.2%

13

19.1%

No

114

83.8%

59

86.8%

55

80.9%

0.486

Polyneuropathy (C 1 symptom)
Absent

92

67.6%

45

66.2%

47

69.1%

Present

44

32.4%

23

33.8%

21

30.9%

Fig. 2 Prevalence of peripheral neuropathy (percentage)

0.855
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Table 4 Factors associated with neuropathy
Overall (N = 136)
OR

95% CI OR

HIV 1 diabetes (N = 68)

HIV only (N = 68)
P value OR

95% CI OR

P value OR

95% CI OR

P value

Age

1.07 [1.02, 1.113]

0.004

1.04 [0.979, 1.102] 0.211

1.09 [1.019, 1.175]

0.014

Gender (female)

0.62 [0.263, 1.468]

0.278

0.55 [0.145, 2.094] 0.382

0.72 [0.23, 2.245]

0.57

BMI (continuous)

0.98 [0.911, 1.053]

0.577

0.99 [0.945, 1.044] 0.776

0.93 [0.817, 1.051]

0.238

BMI (underweight)

3.89 [0.221, 68.381] 0.353

–

2.40 [0.124, 46.391] 0.562

BMI (overweight)

1.21 [0.469, 3.118]

0.693

1.25 [0.297, 5.256] 0.761

0.98 [0.268, 3.602]

0.978

BMI (obese)

0.58 [0.16, 2.073]

0.399

1.05 [0.166, 6.604] 0.962

0.30 [0.049, 1.82]

0.19

Duration of HIV

1.07 [0.996, 1.151]

0.063

1.08 [0.96, 1.219]

0.198

1.06 [0.962, 1.156]

0.258

CD4 count diagnosis 1.00 [0.999, 1.002]

0.699

1.00 [0.998, 1.003] 0.744

1.00 [0.998, 1.002]

0.962

CD4 count last

1.00 [0.999, 1.002]

0.394

1.00 [0.999, 1.004] 0.287

1.00 [0.999, 1.001]

0.931

RNA (undetected)

1.15 [0.46, 2.868]

0.767

0.43 [0.114, 1.613] 0.21

2.77 [0.704, 10.905] 0.145

–

–

BMI body mass index, RNA ribonucleic acid

amongst women in the USA living with HIV in
2009. After multivariate analysis, DM was associated with an OR of 1.45 (95% CI 1.02–2.08,
p = 0.04) in HIV DSP [27]. Similar findings were
reported earlier in 2005 in a large cohort of 2515
patients in the same country with a reported OR
of 1.79 (95% CI 1.12–2.84, p = 0.014 [28].
Although our study supports the notion that
DM increases the risk of PN in HIV, the sampling technique does not enable analysis of the
degree of risk conferred. Most of the patients
with DM were diagnosed because of routine
random blood sugar checks or HbA1c while
undergoing follow-up for HIV infection. The
relatively short duration of DM follow-up and
well-controlled diabetes is a consequence of
screening.
The median age was higher in the HIV and
DM group compared to the HIV-only group.
Older age was associated with PN with an OR of
1.04 and 1.09 in the two respective groups. This
association has been clearly demonstrated in
previous studies [15, 19, 23, 25, 26, 28, 29].
These results illustrate the contribution of agerelated degeneration of the nerves to the insults
by HIV, drugs, and other comorbid conditions
like DM (duration) in the occurrence of PN. In
our study, female gender was not associated

with PN in HIV. This was in contrast to a study
done in Kenya that showed an almost tenfold
risk in female individuals [15]. The risk of PN
was noted to be higher in women who were
anemic, proving a possible confounder in the
high risk amongst the female patients in the
study. Other studies in the same region of subSaharan Africa in Rwanda [25] and Zimbabwe
[29] showed no association between female
gender and PN.
The association between the level of HIV
suppression and PN has been controversial in
previous studies. Advanced disease was noted to
be associated with PN in studies done in the
USA with CD4 counts lower than 200 conferring odds of 1.39 and 1.64, respectively [19, 28].
In contrast, no association was demonstrated
between CD4 counts and PN in Kenya [15],
Uganda [26], Rwanda [25], and Zimbabwe [29].
These are generally comparable to the findings
of this study and supportive of the notion that
other factors including nutrition may be contributory to PN in the African population.
Intriguingly, in this study, a suppressed viral
load has a positive impact on PN in the HIV and
DM group with an OR of 2.77. This was not
supportive of the postulated pathogenesis of
HIV DSP as viral invasion and replication in the

Diabetes Ther

peripheral nerves. The potential contribution of
DM as a factor in PN in this subset of patients is
unclear. A longer duration of follow-up had a
slight positive association with the occurrence
of PN in both groups. Significant positive association between the duration of clinical follow
up and PN was demonstrated in a study done in
North America in 2006 [30]. More recent studies
in Rwanda [25] and Nigeria [31] also show the
same association.
The strengths of the study lie in the inclusion of two comparative groups in the evaluation of the burden of PN in patients with HIV.
Previous reports have excluded patients with
diabetes because of the confounding effect on
PN. The concurrent HIV and DM group reflects
the current and future challenges of comorbidities in the HIV population. Furthermore,
the evaluation in relation to age, BMI, and level
of disease control of both HIV and DM allowed
the assessment of risk factors of PN in the participants. Most of the patients studied were
attending regular follow-up clinics and therefore represent a real-world cohort of patients.
The findings are therefore generalizable to
many settings in Kenya and sub-Saharan Africa.
The definition of PN in our study was the presence of both a symptom and a sign using validated and widely utilized criteria.
A limitation of the study was the lack of
electrophysiological tests for nerve function
studies and reliance on clinical evaluation for
the diagnosis of PN. Nerve function tests were
not administered because of financial constraints. Although we documented the prevalence of neuropathic symptoms, the burden of
the disease and the impact on quality of life
were not assessed. Future studies should assess
how neuropathy impacts the patients.

CONCLUSION
Our study demonstrates a higher prevalence of
PN in patients with both HIV and DM when
compared to HIV alone. Physicians should
consider routinely screening patients for PN in
HIV-positive patients with DM.
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